GOSSAMER BIO INC (GOSS)
US38341P1021 - Common Stock
What's going on in today's session
Stay up-to-date with the latest market trends in the middle of the day on Thursday. Explore the top gainers and losers during today's session in our detailed report.
Stay updated with the stocks that are on the move in today's pre-market session.
The US market is yet to commence its session on Thursday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Gossamer Bio Announces Third Quarter 2024 Financial Results and Provides Business Update
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Gossamer Bio Announces Data Presentations at the European Respiratory Society Congress 2024
GOSS Stock Earnings: Gossamer Bio Misses EPS, Misses Revenue for Q2 2024
GOSS stock results show that Gossamer Bio missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.
GOSS Stock Earnings: Gossamer Bio Misses EPS, Misses Revenue for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Gossamer Bio (NASDAQ:GOSS) just reported results for the second quarter of 2024...
Gossamer Bio Announces Second Quarter 2024 Financial Results and Provides Business Update
Tuesday 6/25 Insider Buying Report: GOSS, EXFY
Top Buys by Top Brass: CEO Hasnain's $250.3K Bet on GOSS
The Penny Stock Pundits: 3 Companies Poised to Become the Talk of Wall Street
Taking a small position in these penny stocks today could have you sitting on a sizable gain by the time Wall Street starts to pile in.
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Chiesi y Gossamer Bio anuncian una colaboración global para desarrollar y comercializar seralutinib
Chiesi y Gossamer Bio anuncian una colaboración global transformadora para desarrollar y comercializar seralutinib en la hipertensión arterial pulmonar y otras...
Chiesi und Gossamer Bio kündigen globale Zusammenarbeit zur Entwicklung und Vermarktung von Seralutinib bei pulmonaler arterieller Hypertonie sowie anderen Atemwegsindikationen an
Strategische Zusammenarbeit, um die Führungsposition von Chiesi im Bereich der Atemwege und die Entwicklungskompetenz von Gossamer Bio im Bereich der...
Chiesi et Gossamer Bio annoncent une collaboration mondiale transformatrice pour développer et commercialiser le séralutinib pour l'hypertension artérielle pulmonaire et d'autres indications respiratoires
Collaboration stratégique pour tirer parti de l'héritage de leadership dans les maladies respiratoires de Chiesi et de l'expertise de Gossamer Bio en matière...
GOSS Stock Earnings: Gossamer Bio Misses EPS for Q1 2024
GOSS stock results show that Gossamer Bio missed analyst estimates for earnings per share the first quarter of 2024.
GOSS Stock Earnings: Gossamer Bio Misses EPS for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Gossamer Bio (NASDAQ:GOSS) just reported results for the first quarter of 2024....
Gossamer Bio Announces First Quarter 2024 Financial Results and Provides Business Update
Chiesi and Gossamer Bio Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in Pulmonary Arterial Hypertension and Other Respiratory Indications
Strategic collaboration to leverage Chiesi's legacy of respiratory leadership and Gossamer Bio's development expertise in pulmonary hypertension. Gossamer to...
Gossamer Bio Announces Publication of TORREY Phase 2 Results in the Lancet Respiratory Medicine
Gossamer Bio Announces Appointment of Steven D. Nathan, M.D., and Skye Drynan to its Board of Directors
GOSS Stock Earnings: Gossamer Bio Meets EPS for Q4 2023
GOSS stock results show that Gossamer Bio met analyst estimates for earnings per share the fourth quarter of 2023.
GOSS Stock Earnings: Gossamer Bio Meets EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Gossamer Bio (NASDAQ:GOSS) just reported results for the fourth quarter of 2023...
Gossamer Bio Announces Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
7 Micro-Cap Stocks That Could Majorly Surprise Investors
Although extremely small enterprises can be terrifyingly risky, these micro-cap stock surprises deserve a closer look.
